.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206947

« Back to Dashboard
NDA 206947 describes LENVIMA, which is a drug marketed by Eisai Inc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the LENVIMA profile page.

The generic ingredient in LENVIMA is lenvatinib mesylate. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.

Summary for NDA: 206947

Tradename:
LENVIMA
Applicant:
Eisai Inc
Ingredient:
lenvatinib mesylate
Patents:3

Pharmacology for NDA: 206947

Suppliers and Packaging for NDA: 206947

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL 206947 NDA Eisai Inc. 62856-708 62856-708-30 6 BLISTER PACK in 1 BOX, UNIT-DOSE (62856-708-30) > 10 CAPSULE in 1 BLISTER PACK (62856-708-05)
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL 206947 NDA Eisai Inc. 62856-710 62856-710-30 6 BLISTER PACK in 1 BOX, UNIT-DOSE (62856-710-30) > 5 CAPSULE in 1 BLISTER PACK (62856-710-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 4MG BASE
Approval Date:Feb 13, 2015TE:RLD:No
Patent:7,253,286Patent Expiration:Oct 19, 2021Product Flag?YSubstance Flag?YDelist Request?
Patent:7,612,208Patent Expiration:Sep 19, 2026Product Flag?YSubstance Flag?YDelist Request?
Regulatory Exclusivity Expiration:May 13, 2019
Regulatory Exclusivity Use:EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc